Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Table 1 Characteristics of ADCs for the treatment of urothelial carcinoma

ADCs	Target	mAb	Linker	Payload	DAR
EV	Nectin-4	Enfortumab	vc-PABC linker	MMAE	3.8
SG	Trop2	Sacituzumab	CL2A	SN-38	7.6
RC48	HER2	Hertuzumab	vc-PABC linker	MMAE	4

ADCs Antibody–drug conjugates, CL2A A cleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker, DAR Drug-to-antibody ratio, EV Enfortumab vedotin, HER2 Human epidermal growth factor receptor 2, MMAE Monomethyl auristatin E, RC48 Disitamab vedotin, SG Sacituzumab govitecan, vc-PABC Valyl-citrullinyl-p-aminobenzyloxycarbonyl

ISSN: 1756-8722